Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 15/20 | 1.00 |
| ▸ | PDE7A | Q13946 | 2/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.98 |
| ▸ | PDE4A | P27815 | 14/20 | 0.98 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.98 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564179 | 1.00 | PDE4D (1.00) | PDE4DPDE7APDE3BPDE3APDE4B | |
| SCHEMBL5564177 | 1.00 | PDE4D (1.00) | PDE4DPDE7APDE3BPDE3APDE4B | |
| SCHEMBL5564048 | 0.99 | PDE4B (1.00) | PDE4DPDE7APDE3BPDE3APDE4B | |
| SCHEMBL5564051 | 0.99 | PDE4B (1.00) | PDE4DPDE7APDE3BPDE3APDE4B | |
| SCHEMBL6871258 | 0.99 | PDE4B (1.00) | PDE4DPDE7APDE3BPDE3APDE4B | |
| SCHEMBL5558463 | 0.91 | PDE4D (0.83) | PDE4DPDE7APDE3BPDE3APDE4B | |
| SCHEMBL5558471 | 0.91 | PDE4D (0.83) | PDE4DPDE7APDE3BPDE3APDE4B | |
| SCHEMBL5556835 | 0.91 | PDE4D (0.83) | PDE4DPDE7APDE3BPDE3APDE4B | |
| SCHEMBL5558459 | 0.91 | PDE4D (0.83) | PDE4DPDE7APDE3BPDE3APDE4B | |
| SCHEMBL5556838 | 0.91 | PDE4D (0.83) | PDE4DPDE7APDE3BPDE3APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186710-B2 | Phthalazinones | ALTANA PHARMA AG (DE) | 2007-03-06 | — | — | US | claimed |
| US-20040127707-A1 | PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | US | claimed |
| EP-1385848-A2 | PHTALAZINONES DERIVATIVES USEFUL AS PDE4/7 INHIBITORS | ALTANA Pharma AG (DE) | 2004-02-04 | — | — | EP | claimed |
| WO-2002085906-A2 | PHTHALAZINONES DERIVATIVES USEFUL AS PDE4/7 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | claimed |
| US-7186710-B2 | Phthalazinones | ALTANA PHARMA AG (DE) | 2007-03-06 | — | — | US | disclosed |
| US-20040127707-A1 | PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | US | disclosed |
| EP-1385848-A2 | PHTALAZINONES DERIVATIVES USEFUL AS PDE4/7 INHIBITORS | ALTANA Pharma AG (DE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002085906-A2 | PHTHALAZINONES DERIVATIVES USEFUL AS PDE4/7 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127707-A1 | PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders | PDE4A, PDE4B, PDE7B | PDE4D 5/4885PDE7A 6/4885PDE3B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.